MASA Valve Early Feasibility Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-22
SponsorPECA Labs

About this trial

The MASA Valve Early Feasibility Study (MVEFS) multi-site interventional clinical trial within the United States of America with each center following a common protocol.The objective of the trial is to evaluate the safety and probable benefit of MASA Valve in the indicated subset of patients requiring Right Ventricular Outflow Tract Reconstruction (RVOTR). As an early feasibility study, the purpose is determine the feasibility of success of the device in order to gather early data towards a future pivotal study and/or regulatory clearance submission.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

At least one of the following: Right Ventricular to Pulmonary Artery mean gradient > 35mm Hg, moderate or severe Pulmonary regurgitation (≥3+), or clinical indication for replacement of their native or prosthetic pulmonary valve with a prosthesis.

Age < 22 years

Patient is geographically stable and willing to return for 1 year follow-up for the trial.

Patient's legal guardian should be willing to provide informed consent (IC) at the hospital location where they are being enrolled.

Disqualifiers

Patient is in need of or has presence of a prosthetic heart valve at any other position

Patient has a need for concomitant surgical procedures (non-cardiac)

Patients with previously implanted pacemaker (including defibrillators) or mechanical valves

Patient has an active bacterial or viral infection or requiring current antibiotic therapy (if temporary illness, patient may be a candidate 4 weeks after discontinuation of antibiotics)

Trial design

Design model

Single group

Treatments tested in this trial

  • Surgical Right Ventricular Outflow Tract Reconstruction

    Device

    Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Experimental ArmExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Freedom from device related death

Percentage of patients that have not died related to the device 1 year from implantation

Time frame
1 year
2

Freedom from Explant

Percentage of patients that have not undergone device explant within 1 year from implantation

Time frame
1 year
3

Freedom from Device-Related Reoperation

Percentage of patients that have not undergone re-operation related to the device within 1 year from implantation

Time frame
1 year
4

Freedom from Device-Related Catheter Intervention

Percentage of patients that have not undergone device related catheter based intervention within 1 year from implantation

Time frame
1 year

Secondary outcomes

1

Freedom from Moderate or Greater Pulmonary Regurgitation

Percentage of patients that show less than Moderate Pulmonary Regurgitation within 1 year from implantation on Echocardiographic assessment

Time frame
1 year
2

Freedom from Pulmonary Gradient ≥36mmHg

Percentage of patients that have a Pulmonary Gradient \<= 36mmHg within 1 year from implantation on Echocardiographic assessment

Time frame
1 year
3

Freedom from device valve failure

Percentage of patients that show do not show valve functional failure on Echocardiographic assessment

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.